Human papillomavirus (HPV) is one of the most common sexually transmitted infections. Up to 80% of sexually active women are infected at some point in their lives and infection with specific "high risk" strains of HPV has ...
Sep 16, 2014
0
0
(HealthDay)—Neither parents' nor adolescents' knowledge about human papillomavirus (HPV) vaccines predicts vaccination compliance, according to a study published online Sept. 15 in Pediatrics.
Sep 16, 2014
0
0
A human papillomavirus (HPV) vaccine used in Australia has reduced the prevalence of vaccine-targeted and non-targeted HPV types, researchers have found.
Sep 16, 2014
1
0
GPs in Australia are managing 61 per cent less cases of genital warts among young women since the introduction of the national human papillomavirus (HPV) vaccination program, a new study from the University of Sydney reveals.
Sep 7, 2014
1
0
Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent ...
Aug 22, 2014
0
1
The Food and Drug Administration has approved Genentech's Avastin for a new use against late-stage cervical cancer, the sixth indication for the blockbuster biotech drug.
Aug 15, 2014
0
0
Researchers have hijacked a defense system normally used by bacteria to fend off viral infections and redirected it against the human papillomavirus (HPV), the virus that causes cervical, head and neck, and other cancers.
Aug 9, 2014
0
0
Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus ...
Jul 31, 2014
0
0
Gillian Prue, from the School of Nursing and Midwifery at Queen's University of Belfast, says that the human papillomavirus (HPV) infection is common in men and can lead to genital warts and the development of some head and ...
Jul 30, 2014
0
0
A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted ...
Jul 24, 2014
0
0
